Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 121,433 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Pregnancy Related
Interventions: OPTIMIZE; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy, Learning, Communication
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions: Carboplatin, Paclitaxel, Lapatinib, Cisplatin, Ipsilateral Radiation, Bilateral Radiation, Transoral Surgery; Drug · Radiation · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gonococcal Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 4 more

Conditions: Tobacco Products
Interventions: Tobacco product administration and assessment; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Bipolar Depression
Interventions: Escitalopram, Celecoxib, Placebo; Drug
Lead sponsor: Loyola University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Dry Eye Disease
Interventions: Lifitegrast, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 31
States / cities: Artesia, California • Hemet, California • Lancaster, California + 25 more

Conditions: Fraility, Risk of Falling
Interventions: Not listed
Lead sponsor: BioSensics; Industry
Eligibility: 65 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Tucson, Arizona • Houston, Texas

Conditions: Multiple Sclerosis, Fatigue, Activity, Motor, Quality of Life
Interventions: Cubii elliptical; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hematologic Malignancy
Interventions: Tacrolimus, Methotrexate, Tocilizumab; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Weakness, Hospital Acquired Condition
Interventions: Ambulation; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 60 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Herpes Zoster, Immunologic Deficiency Syndromes
Interventions: Valacyclovir; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Chronic Disease, Drug Drug Interaction, Medication Adherence
Interventions: Educational Materials for Chronic Disease Management Test (CDMT); Other
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Blood And Marrow Transplantation, Adult Respiratory Distress Syndrome
Interventions: Mesenchymal Stem Cells (MSCs); Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Injuries, Traumatic
Interventions: Safe@Home Intervention Group, Usual Care Group; Behavioral · Other
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Smoking, Pulmonary Disease, Chronic Obstructive, Tobacco Use Disorder
Interventions: Standard Smoking Cessation, Extended Nicotine Replacement Therapy, Nicotine replacement therapy; Other · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Bupropion, Healthy Volunteers
Interventions: Isavuconazole, bupropion hydrochloride; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Cancers
Interventions: MABp1; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: celecoxib, erlotinib hydrochloride; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: botulinum type a; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Breast Cancer
Interventions: Pertuzumab, Trastuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 13 more

Search by objective public record fields.

The OPTIMIZE Study: Optimizing Patient Navigation for Perinatal Care

Use of Virtual Reality to Communicate Concepts of Genomics to the General Public

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae

Effects of Cigar Flavors on Measures of Abuse Liability Among Young Adults

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Physical Activity Monitoring in Frailty and Falling

Cubii for Exercise in People With MS

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Dedicated Ambulator-assisted Physical Activity to Improve Hospital Outcome Measures in Elderly Patients

Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Clinical Utility of CDMT Among VillageMD Providers

Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies

Safe@Home: A Self-Management Program for Individuals With TBI and Their Families

Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

A First in Man Study of MABp1 in Patients With Advanced Cancers

Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy